Literature DB >> 15488477

Chronic antidepressant medication attenuates dexamethasone-induced neuronal death and sublethal neuronal damage in the hippocampus and striatum.

Linda E Haynes1, Dave Barber, Ian J Mitchell.   

Abstract

Dexamethasone, a synthetic corticosteroid, which can induce a range of mood disorders including depression and affective psychosis, is toxic to specific hippocampal and striatal neuronal populations. Chronic administration of antidepressants can induce neuroprotective effects, potentially by raising cellular levels of brain-derived neurotrophic factor (BDNF). We accordingly tested the hypothesis that chronic pretreatment of rats (Sprague-Dawley, male) with antidepressants would attenuate dexamethasone-induced neuronal damage as revealed by reductions in the level of neuronal death and in sublethal neuronal damage shown by the increase in the number of MAP-2 immunoreactive neurons. In support of this hypothesis, we demonstrate that chronic treatment with a range of antidepressants prior to dexamethasone administration (0.7 mg/kg, i.p.) attenuated the levels of neuronal death and loss of MAP-2 immunoreactivity in both the hippocampus and striatum. The antidepressants used were: desipramine (8 mg/kg, i.p., tricyclic), fluoxetine (8 mg/kg, i.p., selective serotonin reuptake inhibitor) and tranylcypromine (10 mg/kg, i.p., monoamine oxidase inhibitor) with each drug being injected once per day for 10 days. In contrast, acute injection of none of the antidepressants exerted a protective effect from dexamethasone-associated neuronal damage. Similarly, injection of neither cocaine nor chlordiazepoxide (benzodiazepine) exerted protective effects when injected either chronically or acutely. The observed protection from dexamethasone-induced neuronal damage is in keeping with the potential of chronic antidepressant medication to increase BDNF levels. The potential for dexamethasone to induce disorders of mood by damaging specific neuronal populations in the hippocampus and dorsomedial striatum is discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15488477     DOI: 10.1016/j.brainres.2004.05.117

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  16 in total

1.  Atorvastatin and Fluoxetine Prevent Oxidative Stress and Mitochondrial Dysfunction Evoked by Glutamate Toxicity in Hippocampal Slices.

Authors:  Fabiana K Ludka; Tharine Dal-Cim; Luisa Bandeira Binder; Leandra Celso Constantino; Caio Massari; Carla I Tasca
Journal:  Mol Neurobiol       Date:  2016-04-06       Impact factor: 5.590

2.  Steroid-induced alterations of mood and behavior in children during treatment for acute lymphoblastic leukemia.

Authors:  Carl J Hochhauser; Michael Lewis; Barton A Kamen; Peter D Cole
Journal:  Support Care Cancer       Date:  2005-09-28       Impact factor: 3.603

Review 3.  The glucocorticoid receptor: pivot of depression and of antidepressant treatment?

Authors:  Christoph Anacker; Patricia A Zunszain; Livia A Carvalho; Carmine M Pariante
Journal:  Psychoneuroendocrinology       Date:  2011-04       Impact factor: 4.905

4.  Antidepressants reduce neuroinflammatory responses and astroglial alpha-synuclein accumulation in a transgenic mouse model of multiple system atrophy.

Authors:  Elvira Valera; Kiren Ubhi; Michael Mante; Edward Rockenstein; Eliezer Masliah
Journal:  Glia       Date:  2013-12-06       Impact factor: 7.452

5.  Visual short-term memory binding in Alzheimer's disease and depression.

Authors:  Mario A Parra; Sharon Abrahams; Robert H Logie; Sergio Della Sala
Journal:  J Neurol       Date:  2010-02-17       Impact factor: 4.849

6.  The New Inhibitor of Monoamine Oxidase, M30, has a Neuroprotective Effect Against Dexamethasone-Induced Brain Cell Apoptosis.

Authors:  Shakevia Johnson; Shawna Tazik; Deyin Lu; Chandra Johnson; Moussa B H Youdim; Junming Wang; Grazyna Rajkowska; Xiao-Ming Ou
Journal:  Front Neurosci       Date:  2010-11-02       Impact factor: 4.677

7.  Alzheimer's disease, but not ageing or depression, affects dual-tasking.

Authors:  Reiner Kaschel; Robert H Logie; Miguel Kazén; Sergio Della Sala
Journal:  J Neurol       Date:  2009-06-19       Impact factor: 4.849

8.  Assessing the neuronal serotonergic target-based antidepressant stratagem: impact of in vivo interaction studies and knockout models.

Authors:  R Rajkumar; R Mahesh
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

9.  A possible role for the endocannabinoid system in the neurobiology of depression.

Authors:  Gino Serra; Walter Fratta
Journal:  Clin Pract Epidemiol Ment Health       Date:  2007-11-19

10.  The effect of imipramine, ketamine, and zinc in the mouse model of depression.

Authors:  Andrzej Wróbel; Anna Serefko; Piotr Wlaź; Ewa Poleszak
Journal:  Metab Brain Dis       Date:  2015-07-10       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.